Video
Dr. Michael Mauro on Treatment Discontinuation for CML
Author(s):
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.
Michael Mauro, MD
,
discusses treatment discontinuation for patients with chronic myeloid leukemia (CML)
hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, .
TKI
s
Treatment with a can offer a “functional cure,” for some CML patients, aid Mauro. After a period of treatment, some patients may be able to discontinue TKI therapy.
,
If patients have a good response to therapy without any degree of relapse, lower-risk disease at presentation, and a period of time in a deep molecular remission, they may be a candidate for treatment discontinuation. On average about half of the patients that fit that criteria may be able to stop TKI therepy without having significant relapse.
<<<
View more from the 2015 Congress on Hematologic Malignancies
